Menu
1-702-720-6310 info@microcapspecualtors.com

Stemline Therapeutics’ SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds

[GlobeNewswire] – NEW YORK, June 04, 2016– Stemline Therapeutics, Inc. announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid …
Source: New feed

Search